Although IS-treatment may have beneficial effects on MuSK-MG and AChR-MG with different mechanisms, in AChR-MG, IS-treatment appears to be preferentially down-regulating Th1 type immune responses. The gene discussed is MUSK; the disease is myasthenia gravis.